TPOXX for Smallpox

"TPOXX was first trialled in 2022 at Meridian Clinical Research, with 5 completed trials as of now. 3 more trials are underway and recruiting patients from Miami, Florida and other locations."

"This study requires 445 patients that meet the eligibility requirements. The sponsor, SIGA Technologies, will be conducting the trial at various sites; two examples are Clinical Pharmacology of Miami, LLC and Midwest Clinical Research Center."

"The primary outcome SIGA Technologies plans to measure over the course of 60 days is clinical laboratory tests. Additionally, this trial will be measuring secondary outcomes including AUC tau, Cmin, and Cavg."

"3 studies concerning TPOXX are currently underway, with locations in 9 cities and 1 nation. The initial study, which occurred in 2022 and was sponsored by SIGA Technologies, involved 100 patients. It completed Phase 2 drug approval and 5 more studies have been conducted since then."

"To make participation more convenient for patients, this study is running at 8 locations. If you live near Miami, Dayton or North Charleston, there is likely a trial site close to you. Additionally, there are 8 other sites located across the United States of America."

"That is true. The website clinicaltrials.gov has the latest information on this trial, which began recruiting on 29 March 2022. As of 6 October 2020, the study needs 445 more participants from 8 different locations."

"To be eligible for this smallpox clinical trial, candidates must meet the age criteria of being between 18-80 years old. There are a total of 445 spots available."

"As this clinical trial's inclusion criteria state, eligible participants must be between 18 to 80 years old."

"TPOXX is currently in Phase 3 trials, which implies that while there is data supporting its efficacy, multiple rounds of testing are required to confirm its safety. Our team gives it a score of 3."